Collectively, these results further support the conclusion that LILRB4 promotes PCa progression via the NF‐κB and PI3K/AKT signalling pathways, positioning LILRB4 as a promising therapeutic target for PCa. This evidence concerns the gene AKT1 and posterior cortical atrophy.